Considering several other mechanisms used by MDSC to inhibit pathogenic T cell response including up-regulation of cyclooxigenase-2 and prostaglandin E2 [20], production of TGF-β [21], [22], depletion of cystein [23], and down-regulation of T cell L-selectin expression [24], especially in tumor models, future work is needed to investigate whether one or more mechanisms are utilized by MDSC to inhibit diabetogenic T cell response in our system. The gene discussed is SELL; the disease is neoplasm.